Subiu de 1.20 para 4.92 dólares! :o
------------------------------------------------------------------------
Spherix Up on Plans for Clinical Trial
Spherix Shares Up After FDA Says Co. Qualified to Begin Late-Stage Clinical Trials for Naturlose
BELTSVILLE, Md. (AP) -- Shares of Spherix Inc. jumped Wednesday to a new 52-week high after the provider of biotech and information technology services said that the Food and Drug Administration told the company it was qualified to begin late-stage clinical trials for a sugar aimed at diabetics.
ADVERTISEMENT
Spherix shares rose $1.40, or 37 percent, to $5.15 in afternoon trading on the Nasdaq at more than 100 times their average volume. Shares hit a new 52-week high of $5.85, surpassing the old one of $3.95 set last December, after sliding to a recent 52-week low of $1.19. Company shares are up 59 percent on the year so far.
The company said that the FDA reviewed data from its early and mid-stage clinical trials for Naturlose, the brand name for the low-calorie natural sugar tagatose. The Phase III clinical trial would study the use of Naturlose in patients with Type 2 diabetes, or adult-onset diabetes where the body does not properly use insulin and produces low levels of the hormone.
With a successful Phase III trial, the company said it would submit an application to the FDA to market the sweetener.